Gypenosides ameliorate ductular reaction and liver fibrosis via inhibition of hedgehog signaling

Gypenosides ameliorate ductular reaction and liver fibrosis via inhibition of hedgehog signaling

Backgroud and aims: Ductular reaction (DR) is a common pathological change and thought to have a key role in the pathogenesis and progression of liver fibrosis. Our previous study reported Gypenosides (GPs) ameliorated liver fibrosis, however, the anti-fibrotic mechanisms of GPs are still unclear.Me...

Full description

Bibliographic Details
Main Authors:	Yonghong Hu, Xiaoli He, Xiaoxi Zhou, Yue Liang, Yadong Fu, Linzhang Zhang, Jing Fang, Wei Liu, Gaofeng Chen, Yongping Mu, Hua Zhang, Hong Cai, Chenghai Liu, Ping Liu, Jiamei Chen
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Pharmacology
Subjects:	gypenosides liver fibrosis ductular reaction hedgehog signaling NPLC0393
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2022.1033103/full

Similar Items

Gypenoside L and Gypenoside LI Inhibit Proliferation in Renal Cell Carcinoma via Regulation of the MAPK and Arachidonic Acid Metabolism Pathways
by: Hui Liu, et al.
Published: (2022-03-01)

Astragalus saponins and its main constituents ameliorate ductular reaction and liver fibrosis in a mouse model of DDC-induced cholestatic liver disease
by: Linzhang Zhang, et al.
Published: (2022-10-01)

Peritumoral ductular reaction can be a prognostic factor for intrahepatic cholangiocarcinoma
by: Zhenyang Shen, et al.
Published: (2020-10-01)

The potential molecular mechanism underlying gypenoside amelioration of atherosclerosis in ApoE−/− mice: A multi-omics investigation
by: Xing Ju, et al.
Published: (2024-04-01)

Mucosal-associated invariant T cells promote ductular reaction through amphiregulin in biliary atresiaResearch in context
by: Man-Huan Xiao, et al.
Published: (2024-05-01)

Gypenoside alleviates injury of rat adrenal pheochromocytoma cell line PC12 induced by lipopolysaccharide
by: JIANG Xiu-fang, GENG Ya-nan, YANG Sheng-hong, WEI Ping, ZHAO Ming, ZHU Ling-ling
Published: (2022-06-01)

Reversine attenuates cholestatic ductular reaction in rats
by: Di Huang, et al.
Published: (2023-05-01)

Ductular Reactions in Liver Injury, Regeneration, and Disease Progression—An Overview
by: Nirmala Mavila, et al.
Published: (2024-03-01)

Gypenosides Attenuate Pulmonary Fibrosis by Inhibiting the AKT/mTOR/c-Myc Pathway
by: Suqing Liu, et al.
Published: (2022-01-01)

Effects of light quality on growth, total gypenosides accumulation and photosynthesis in <em>Gynostemma pentaphyllum</em>
by: Xiaolie Peng, et al.
Published: (2017-07-01)

Costunolide alleviated DDC induced ductular reaction and inflammatory response in murine model of cholestatic liver disease
by: Juan Hao, et al.
Published: (2023-07-01)

Effect of Gypenosides on the composition of gut microbiota and metabolic activity in the treatment of CCl4-induced liver injury in rats
by: Pengyao Tian, et al.
Published: (2022-10-01)

Gypenoside inhibits gastric cancer proliferation by suppressing glycolysis via the Hippo pathway
by: Li Pan, et al.
Published: (2024-08-01)

Label-free proteomic analysis reveals the hepatoprotective mechanism of gypenosides in liver injury rats
by: Yu Chen, et al.
Published: (2024-06-01)

Enhanced Production of Gypenoside LXXV Using a Novel Ginsenoside-Transforming β-Glucosidase from Ginseng-Cultivating Soil Bacteria and Its Anti-Cancer Property
by: Chang-Hao Cui, et al.
Published: (2017-05-01)

Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice
by: Shu‐Chen Cheng, et al.
Published: (2024-03-01)

Yap signalling regulates ductular reactions in mice with CRISPR/Cas9-induced glycogen storage disease type Ia
by: Yixia Xie, et al.
Published: (2022-11-01)

Gypenosides Prevent and Dissolve Cholesterol Gallstones by Modulating the Homeostasis of Cholesterol and Bile Acids
by: Qian Zhuang, et al.
Published: (2022-04-01)

Hybrid sequencing of the Gynostemma pentaphyllum transcriptome provides new insights into gypenoside biosynthesis
by: Tongtong Liang, et al.
Published: (2019-08-01)

CD24+LCN2+ liver progenitor cells in ductular reaction contributed to macrophage inflammatory responses in chronic liver injury
by: Wei-Jian Huang, et al.
Published: (2023-10-01)

Gypenosides Inhibit Inflammatory Response and Apoptosis of Endothelial and Epithelial Cells in LPS-Induced ALI: A Study Based on Bioinformatic Analysis and in vivo/vitro Experiments
by: Tu Q, et al.
Published: (2021-01-01)

Gypenosides attenuate lipopolysaccharide-induced neuroinflammation and anxiety-like behaviors in rats
by: Bombi Lee, et al.
Published: (2018-09-01)

Gypenoside granules alleviate vascular smooth muscle cell phenotypic switching in atherosclerosis through impeding MAPK/KLF4 pathway
by: Zhi-Wei Zhao, et al.
Published: (2024-11-01)

Gypenosides Synergistically Reduce the Extracellular Matrix of Hepatic Stellate Cells and Ameliorate Hepatic Fibrosis in Mice
by: Han Li, et al.
Published: (2023-07-01)

Gypenosides ameliorate high-fat diet-induced nonalcoholic fatty liver disease in mice by regulating lipid metabolism
by: Tingting Zhou, et al.
Published: (2023-04-01)

Comprehensive serum metabolomics and network analysis to reveal the mechanism of gypenosides in treating lung cancer and enhancing the pharmacological effects of cisplatin
by: Yan-Shuang Qi, et al.
Published: (2022-12-01)

β-Catenin-NF-κB-CFTR interactions in cholangiocytes regulate inflammation and fibrosis during ductular reaction
by: Shikai Hu, et al.
Published: (2021-10-01)

Hepatoprotective effect of genistein against dimethylnitrosamine-induced liver fibrosis in rats by regulating macrophage functional properties and inhibiting the JAK2/STAT3/SOCS3 signaling pathway
by: Ying Xu, et al.
Published: (2021-12-01)

Gypenoside XVII protects against myocardial ischemia and reperfusion injury by inhibiting ER stress–induced mitochondrial injury
by: Yingli Yu, et al.
Published: (2021-11-01)

Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation
by: Hongshan Li, et al.
Published: (2022-08-01)

Gypenoside XLIX Ameliorate High-Fat Diet-Induced Atherosclerosis via Regulating Intestinal Microbiota, Alleviating Inflammatory Response and Restraining Oxidative Stress in ApoE<sup>−/−</sup> Mice
by: Ming Gao, et al.
Published: (2022-08-01)

Gypenoside-14 Reduces Depression via Downregulation of the Nuclear Factor Kappa B (NF-kB) Signaling Pathway on the Lipopolysaccharide (LPS)-Induced Depression Model
by: Yaqun Jiang, et al.
Published: (2023-08-01)

Ferroptosis in Chronic Liver Diseases: Opportunities and Challenges
by: Xiaoxi Zhou, et al.
Published: (2022-06-01)

Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides
by: Yang G, et al.
Published: (2019-04-01)

Feedback Signaling between Cholangiopathies, Ductular Reaction, and Non-Alcoholic Fatty Liver Disease
by: Tianhao Zhou, et al.
Published: (2021-08-01)

Platelet-rich plasma combined with gypenosides for the treatment of psoriasis-like inflammation in mice
by: LI Dandan, et al.
Published: (2024-12-01)

Gypenoside Inhibits Bovine Viral Diarrhea Virus Replication by Interfering with Viral Attachment and Internalization and Activating Apoptosis of Infected Cells
by: Guanghui Yang, et al.
Published: (2021-09-01)

Gypenoside LVI attenuates foam cell formation by promoting cholesterol export and inhibiting inflammation response
by: Chun-Yan Shen, et al.
Published: (2018-11-01)

Development of LC-FAIMS-MS and its application to lipidomics study of Acinetobacter baumannii infection
by: Jianjun Li, et al.
Published: (2024-11-01)

Gypenoside XVII Reduces Synaptic Glutamate Release and Protects against Excitotoxic Injury in Rats
by: Cheng-Wei Lu, et al.
Published: (2024-05-01)